Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. Rastogi P, Tang G, Hassan S, Geyer CE Jr, et al. Breast Cancer Res Treat 2023;199:243-252.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rastogi P, Tang G, Hassan S, Geyer CE Jr, et al. Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. Breast Cancer Res Treat 2023;199:243-252.
PMID: 36944848